Reven Pharmaceuticals Stock

Reven Pharmaceuticals is a startup developing solutions for the treatment of cardiovascular and circulatory-related conditions.

About Reven Pharmaceuticals Stock

Reven Pharmaceuticals, Inc. is a development-stage bio-pharmaceutical company that develops and markets propriety solutions for the treatment of cardiovascular and circulatory related conditions. These non-surgical, minimally invasive treatments have shown to improve vascular function and circulation without invasive medical procedures, such as atherectomy or balloon angioplasty and stents.

Funding History

January 2014	$1.8M
February 2015	$4.4M

Management

Vice President, Regulatory and Quality Affairs

Brian Denomme

Co-Founder and Chief Executive Officer

Michael K. Handley

Vice President of Operations

Mariëtte Luïse Van Wyk

President

Peter Lange

Other Companies

Learn More

Aura Biosciences

Development of drugs by using tumor targeted Pseudovirions

$112MTotal Funding

Learn More

EPINEX DIAGNOSTICS

Epinex Diagnostics is a medical diagnostics company developing products for the identification of diabetes.

$4.6MTotal Funding

Learn More

Tute Genomics

Cloud-based genomics testing platform

$7.7MTotal Funding

Learn More

Vedanta Biosciences

Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.

$55.4MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Reven Pharmaceuticals or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.